))
Episode: 8 - The Financial Impact of a Continuous Bioprocessing Strategy
Manage episode 360369297 series 3394448
Innehåll tillhandahållet av Evaluating Biopharma. Allt poddinnehåll inklusive avsnitt, grafik och podcastbeskrivningar laddas upp och tillhandahålls direkt av Evaluating Biopharma eller deras podcastplattformspartner. Om du tror att någon använder ditt upphovsrättsskyddade verk utan din tillåtelse kan du följa processen som beskrivs här https://sv.player.fm/legal.
Joseph Shultz, VP and technical head of biologics and vaccines at Resilience, and John Bonham-Carter, board member and VP of business development and product management at Erbi Biosystems, discuss the financial considerations biopharma companies face when implementing a continuous strategy. Shultz talks about the mindset of the senior leadership at Amgen—and then Novartis—that lead to the eventual adoption of a new bioprocessing system and how their strategies benefit multiple teams within a single organization. He also discusses the importance of setting key milestones to track successes and failures, the business parameters best suited for continuous bioprocessing, and the real and imagined hurdles associated with continuous over batch processing.
Links from this episode:
Evaluating Biopharma
Resilience
Erbi Biosystems
Evaluating Biopharma boiler: Evaluating Biopharma taps into the insight and experience of biopharmaceutical leaders so today’s decision makers can leverage their knowledge, learn from their successes, and avoid repeating similar mistakes. This series offers a new guest and moderator with each episode and aims to equip executives and science leaders with the necessary information to make better business and process decisions. The Evaluating Biopharma podcast is a reproduction of content originally presented at recent Evaluating Biopharma digital and educational networking events.
24 episoder
Dela
